Harmless soil-dwelling bacteria successfully kill cancer

	Tweet

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology’s Autumn Conference at the University of York.

The therapy uses Clostridium sporogenes – a bacterium that is widespread in the soil. Spores of the bacterium are injected into patients and only grow in solid tumours, where a specific bacterial enzyme is produced. An anti-cancer drug is injected separately into the patient in an inactive ‘pro-drug’ form. When the pro-drug reaches the site of the tumour, the bacterial enzyme activates the drug, allowing it to destroy only the cells in its vicinity – the tumour cells.

Researchers at the University of Nottingham and the University of Maastricht have now overcome the hurdles that have so far prevented this therapy from entering clinical trials. They have introduced a gene for a much-improved version of the enzyme into the C. sporogenes DNA. The improved enzyme can now be produced in far greater quantities in the tumour than previous versions, and is more efficient at converting the pro-drug into its active form.

A fundamental requirement for any new cancer therapy is the ability to target cancer cells while excluding healthy cells. Professor Nigel Minton, who is leading the research, explains how this therapy naturally fulfils this need. “Clostridia are an ancient group of bacteria that evolved on the planet before it had an oxygen-rich atmosphere and so they thrive in low oxygen conditions. When Clostridia spores are injected into a cancer patient, they will only grow in oxygen-depleted environments, i.e. the centre of solid tumours. This is a totally natural phenomenon, which requires no fundamental alterations and is exquisitely specific. We can exploit this specificity to kill tumour cells but leave healthy tissue unscathed,” he said.

The research may ultimately lead to a simple and safe procedure for curing a wide range of solid tumours. “This therapy will kill all types of tumour cell. The treatment is superior to a surgical procedure, especially for patients at high risk or with difficult tumour locations,” explained Professor Minton. “We anticipate that the strain we have developed will be used in a clinical trial in 2013 led by Jan Theys and Philippe Lambin at the University of Maastricht in The Netherlands. A successful outcome could lead to its adoption as a frontline therapy for treating solid tumours. If the approach is successfully combined with more traditional approaches this could increase our chance of winning the battle against cancerous tumours.”

###

Contact: Laura Udakis

44-118-988-1843
Society for General Microbiology

RELATED STORIES:
Unlocking the body’s defenses against cancer   Mayo Clinic Researchers Find That Protein Believed to Protect Against Cancer Has a Mr. Hyde Side   Study Quantifies Racial Disparities in Cancer Mortality Rates   Simple test could hold key to early diagnosis of cancers   Telephone Calls Increase Cancer Screening Rates   Oral Form of Anti-cancer Agent Shows Promise in Treating Sarcoma   Active lifestyle may prevent cancer: Japan study   Cancer research summaries   How to recognize at an early stage whether a new cancer therapy prolongs life   Researchers find roadmap to next-generation cancer therapies   Post-cancer treatment needs go unmet in some   Teenagers and young adults more likely to survive cancer in Australia than in the USA   Improving Cancer Diagnosis   Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers   Finding the Right Radiation Facility Is Critical for Cancer Patients   Back to School Program Helps Kids with Cancer   Penn Study on Silencing of Tumor Suppressor Gene Suggests New Target for Lymphoma   Five Low-Cost Ways to Prevent Cancer   PCB exposure may raise lymphoma risk   Rare cancer cells captured by imaging device   Lance Armstrong: Cancer a global problem   Custom-made cancer cell attacks

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]